Clinical Trial Detail

NCT ID NCT02246621
Title A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib + Anastrozole + Letrozole

Anastrozole + Letrozole

Age Groups: adult

Additional content available in CKB BOOST